-One-Year Final Data Highlights Lead Cell Therapy Asset, CAP-1002, for Safety and Efficacy in Slowing Upper Limb and Cardiac Function Deterioration in Patients- -Data Sets Stage for Pivotal Phase 3 ...
-Partnership Leverages Nippon Shinyaku’s Deep Experience in Drug Development for Rare Diseases and its Commercial DMD Franchise in the U.S.- -Capricor to Receive an Upfront Payment of $30 Million, Additional ...
Copyright © 2015 - 2021 Lifecarenews.in
